BIND Therapeutics reports income of $2.1 million for fourth quarter 2013 BIND Therapeutics, Inc tadalafil for sale . , a clinical-stage nanomedicine system business developing programmable and targeted therapeutics called AccurinsTM, reported financial outcomes for the fourth one fourth and year-ended December 31 today, 2013. 2013 was a transformative calendar year for BIND as we produced significant progress towards offering improved treatment plans for patients with malignancy, stated Scott Minick, BIND's CEO and President. We initiated two Stage 2 studies with this lead product applicant, BIND-014, in both metastatic castrate resistant prostate malignancy and non-little cell lung tumor.
Economic Influence of Advanced Biofuels Creation, projects that advancement of advanced biorefineries could create as much as 29,000 careers over another few years.. BIO releases proposed plan options to aid U.S. The Biotechnology Industry Firm today released proposed plan options offering needed incentives to aid U.S. Job development incentivizing commercial level biorefinery projects for creation of advanced biofuels, biobased items and renewable specialty chemical substances. Industrial biotechnology solutions for advanced biofuels are prepared, and companies have attained significant successes in attaining analysis and development goals.